Soft Tissue Sarcomas: New Opportunity of Treatment with PARP Inhibitors?

Overview

Journal Radiol Med

Specialty Radiology

Date 2018 Mar 28

PMID 29582320

Citations 11

Authors

Monica Mangoni

Mariangela Sottili

Giulia Salvatore

Domenico Campanacci

Guido Scoccianti

Giovanni Beltrami

Camilla Delli Paoli

Luca Dominici

Virginia Maragna

Emanuela Olmetto

Icro Meattini

Isacco Desideri

Pierluigi Bonomo

Daniela Greto

Lorenzo Livi

Affiliations

Soon will be listed here.

Abstract

Background: Poly(ADP-ribose) polymerases (PARP) are a large family of enzymes involved in several cellular processes, including DNA single-strand break repair via the base-excision repair pathway. PARP inhibitors exert antitumor activity by both catalytic PARP inhibition and PARP-DNA trapping, moreover PARP inhibition represents a potential synthetic lethal approach against cancers with specific DNA-repair defects. Soft tissue sarcoma (STSs) are a heterogeneous group of mesenchymal tumors with locally destructive growth, high risk of recurrence and distant metastasis.

Objectives: The purpuse of this review is to provide an overview of the main preclinical and clinical data on use of PARPi in STSs and of effect and safety of combination of PARPi with irradiation.

Results: Due to numerous genomic alterations in STSs, the DNA damage response pathway can offer an interesting target for biologic therapy. Preclinical and clinical studies showed promising results, with the most robust evidences of PARPi efficacy obtained on Ewing sarcoma bearing EWS-FLI1 or EWS-ERG genomic fusions. The activity of PARP inhibitors resulted potentiated by chemotherapy and radiation. Although mechanisms of synergisms are not completely known, combination of radiation therapy and PARP inhibitors exerts antitumor effect by accumulation of unrepaired DNA damage, arrest in G2/M, activity both on oxic and hypoxic cells, reoxygenation by effect on vessels and promotion of senescence. Early trials have shown a good tolerance profile.

Conclusions: The use of PARP inhibitors in advanced stage STSs, alone or combined in multimodal treatments, is of great interest and warrants further investigations.

Citing Articles

Expression of DNA Repair Genes in Ewing Sarcoma.

Kyriazoglou A, Moutafi M, Zografos E, Konteles V, Sofianidis G, Mahaira L Cancer Diagn Progn. 2024; 4(3):231-238.

PMID: 38707718 PMC: 11062174. DOI: 10.21873/cdp.10313.

Revisiting 'Hallmarks of Cancer' In Sarcomas.

Honoki K, Tsujiuchi T, Kishi S, Kuniyasu H J Cancer. 2024; 15(7):1786-1804.

PMID: 38434982 PMC: 10905407. DOI: 10.7150/jca.92844.

The oncogenic fusion protein TAZ::CAMTA1 promotes genomic instability and senescence through hypertranscription.

Neil E, Paredes R, Pooley O, Rubin B, Kouskoff V Commun Biol. 2023; 6(1):1174.

PMID: 37980390 PMC: 10657451. DOI: 10.1038/s42003-023-05540-4.

The Outcome of Discontinuing Tyrosine Kinase Inhibitors in Advanced Sarcoma Following a Favorable Tumor Response to Antiangiogenics Therapy.

Zhang Z, Bao Q, Fu Y, Wen J, Li M, Liu Z J Clin Med. 2023; 12(1).

PMID: 36615127 PMC: 9821264. DOI: 10.3390/jcm12010325.

Radiomics in the Setting of Neoadjuvant Radiotherapy: A New Approach for Tailored Treatment.

Nardone V, Boldrini L, Grassi R, Franceschini D, Morelli I, Becherini C Cancers (Basel). 2021; 13(14).

PMID: 34298803 PMC: 8303203. DOI: 10.3390/cancers13143590.

References

Lockett K, Craig Hall M, Xu J, Zheng S, Berwick M, Chuang S . The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res. 2004; 64(17):6344-8. DOI: 10.1158/0008-5472.CAN-04-0338. View

Brenner J, Ateeq B, Li Y, Yocum A, Cao Q, Asangani I . Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011; 19(5):664-78. PMC: 3113473. DOI: 10.1016/j.ccr.2011.04.010. View

Gibault L, Perot G, Chibon F, Bonnin S, Lagarde P, Terrier P . New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics. J Pathol. 2010; 223(1):64-71. DOI: 10.1002/path.2787. View

Shunkwiler L, Ferris G, Kunos C . Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair. Int J Mol Sci. 2013; 14(2):3773-85. PMC: 3588069. DOI: 10.3390/ijms14023773. View

Sonnenblick A, de Azambuja E, Azim Jr H, Piccart M . An update on PARP inhibitors--moving to the adjuvant setting. Nat Rev Clin Oncol. 2014; 12(1):27-41. DOI: 10.1038/nrclinonc.2014.163. View

Vormoor B, Curtin N . Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma. Curr Opin Oncol. 2014; 26(4):428-33. PMC: 4059819. DOI: 10.1097/CCO.0000000000000091. View

Gani C, Coackley C, Kumareswaran R, Schutze C, Krause M, Zafarana G . In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio. Radiother Oncol. 2015; 116(3):486-94. DOI: 10.1016/j.radonc.2015.08.003. View

Verhagen C, de Haan R, Hageman F, Oostendorp T, Carli A, OConnor M . Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015; 116(3):358-65. DOI: 10.1016/j.radonc.2015.03.028. View

Reiss K, Herman J, Armstrong D, Zahurak M, Fyles A, Brade A . A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in.... Gynecol Oncol. 2017; 144(3):486-490. PMC: 5330287. DOI: 10.1016/j.ygyno.2017.01.016. View

10.

Wang L, Liang C, Li F, Guan D, Wu X, Fu X . PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs. Int J Mol Sci. 2017; 18(10). PMC: 5666793. DOI: 10.3390/ijms18102111. View

11.

Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer P, Powell S . Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res. 2008; 68(2):605-14. DOI: 10.1158/0008-5472.CAN-07-5472. View

12.

Norris R, Adamson P, Nguyen V, Fox E . Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors. Pediatr Blood Cancer. 2013; 61(1):145-50. PMC: 3849815. DOI: 10.1002/pbc.24697. View

13.

Lim J, Tan D . Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers (Basel). 2017; 9(8). PMC: 5575612. DOI: 10.3390/cancers9080109. View

14.

Engert F, Kovac M, Baumhoer D, Nathrath M, Fulda S . Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. Oncotarget. 2016; 8(30):48794-48806. PMC: 5564725. DOI: 10.18632/oncotarget.10720. View

15.

Steppan D, Pratilas C, Loeb D . Targeted therapy for soft tissue sarcomas in adolescents and young adults. Adolesc Health Med Ther. 2017; 8:41-55. PMC: 5384699. DOI: 10.2147/AHMT.S70377. View

16.

Rimondi E, Benassi M, Bazzocchi A, Balladelli A, Facchini G, Rossi G . Translational research in diagnosis and management of soft tissue tumours. Cancer Imaging. 2016; 16(1):13. PMC: 4897899. DOI: 10.1186/s40644-016-0071-7. View

17.

Murai J, Huang S, Das B, Renaud A, Zhang Y, Doroshow J . Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72(21):5588-99. PMC: 3528345. DOI: 10.1158/0008-5472.CAN-12-2753. View

18.

Chabot P, Hsia T, Ryu J, Gorbunova V, Belda-Iniesta C, Ball D . Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. J Neurooncol. 2016; 131(1):105-115. PMC: 5258788. DOI: 10.1007/s11060-016-2275-x. View

19.

Helleday T . The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011; 5(4):387-93. PMC: 5528309. DOI: 10.1016/j.molonc.2011.07.001. View

20.

Laroche A, Chaire V, Le Loarer F, Algeo M, Rey C, Tran K . Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas. J Hematol Oncol. 2017; 10(1):84. PMC: 5387279. DOI: 10.1186/s13045-017-0451-x. View